14 Most Undervalued NASDAQ Stocks to Buy Now

Page 6 of 14

9. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Forward P/E Ratio as of September 20: 5.97

Number of Hedge Fund Holders: 46

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the most undervalued NASDAQ stocks to buy now. Piper Sandler reaffirmed its Overweight rating and $147 price target for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on September 15 in expectation of data from the upcoming clinical trial. Jazz is gearing up to report progression-free survival data from its HERIZON-GEA-01 study in the fourth quarter of 2025. The trial assesses zanidatamab as the first-line therapy for advanced/metastatic gastroesophageal adenocarcinoma.

To talk about the possible results of the experiment, Piper Sandler recently convened a webinar with a top oncologist experienced with gastroesophageal adenocarcinoma. According to the specialist’s evaluation, Piper Sandler believes that should the trial’s outcomes be favorable, zanidatamab may be able to establish a sizable commercial presence in the treatment market.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company that develops treatments for serious illnesses. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos.

Page 6 of 14